ATOSSA THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(amounts in thousands, except share data)
| Convertible Preferred Stock · Common Stock · Treasury Stock | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Total | ||||||||
| Shares | Amount | Shares | Amount | Paid-inCapital | Amount | AccumulatedDeficit | Stockholders'Equity | |
| Balance at December 31, 2021 | 582 | $— | 126,624,110 | $22,792 | $244,578 | $— | $(129,234) | $138,136 |
| Stock-based compensation | — | — | — | — | 6,788 | — | — | 6,788 |
| Net loss | — | — | — | — | — | — | (26,960) | (26,960) |
| Balance at December 31, 2022 | 582 | $— | 126,624,110 | $22,792 | $251,366 | $— | $(156,194) | $117,964 |
| Common stock repurchased | — | — | (1,320,046) | — | — | (1,475) | — | (1,475) |
| Stock-based compensation | — | — | — | — | 4,621 | — | — | 4,621 |
| Net loss | — | — | — | — | — | — | (30,094) | (30,094) |
| Balance at December 31, 2023 | 582 | $— | 125,304,064 | $22,792 | $255,987 | $(1,475) | $(186,288) | $91,016 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.